ArticleCancer research2017
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
Registry-linked trialAbstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03319459 (FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors), which is not on this map. Cited by 100 papers.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Who cites it
100 citing papers in PubMed, 138 citations in OpenAlex.
- Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.Nature medicine · 2026Trial
- Nur77 agonism invigorates Natural Killer cell immunity against hepatocellular carcinoma.Nature communications · 2026Article
- GSK-3 regulates CD4-CD8 cooperation for super-armed CD8+ cytolytic T cells in immunotherapy against tumors.Signal transduction and targeted therapy · 2026Article
- Transcriptional networks weaving natural killer anti-tumor immune response.Molecular cancer · 2026Review
- Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication.Cancer cell international · 2026Review
- Multiplexed iPSC platform for advanced NK cell immunotherapies.Cell reports. Medicine · 2025Review
- Engineered natural killer cells for cancer therapy.Cancer cell · 2025Review
- Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.Journal of translational medicine · 2025Review
- Nanomaterials Trigger Functional Anti-Tumoral Responses in Primary Human Immune Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application.Frontiers in oncology · 2025Review
- Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer.British journal of cancer · 2024Article
- Arachidonic acid impairs natural killer cell functions by disrupting signaling pathways driven by activating receptors and reactive oxygen species.Cell communication and signaling : CCS · 2024Article
- Targeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) enhances CD8 T-cell-reactivity against neuroblastoma cells.Scientific reports · 2024Article
- Reprogramming natural killer cells for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis.Journal of medicinal chemistry · 2024Review
- Immunometabolism in cancer: basic mechanisms and new targeting strategy.Cell death discovery · 2024Review
- METTL3-dependent mCell death & disease · 2024Article
- Enhancing the therapeutic efficacy of NK cells in the treatment of ovarian cancer (Review).Oncology reports · 2024Review
- Heat shock protein gp96 drives natural killer cell maturation and anti-tumor immunity by counteracting Trim28 to stabilize Eomes.Nature communications · 2024Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 2 countries.
Frank CichockiDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Bahram ValamehrFate Therapeutics Inc., San Diego, California.
Ryan BjordahlFate Therapeutics Inc., San Diego, California.
Bin ZhangDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Betsy ReznerFate Therapeutics Inc., San Diego, California.
Paul RogersFate Therapeutics Inc., San Diego, California.
Svetlana GaidarovaFate Therapeutics Inc., San Diego, California.
Stacey MorenoFate Therapeutics Inc., San Diego, California.
Katie TuiningaDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Phillip DoughertyDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Valarie McCullarDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Peter HowardDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Dhifaf SarhanDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Emily TarasDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Heinrich SchlumsCentre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Stewart AbbotFate Therapeutics Inc., San Diego, California.
Daniel ShoemakerFate Therapeutics Inc., San Diego, California.
Yenan T BrycesonCentre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Bruce R BlazarDepartment of Pediatrics, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Scott WolchkoFate Therapeutics Inc., San Diego, California.
Sarah CooleyDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Jeffrey S MillerDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota. mille011@umn.edu.
University of Minnesota · USFate Therapeutics (United States) · USKarolinska University Hospital · SE
Funding
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1995 to 2026
$48.2MTherapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2MViral priming and targeting NK cells against solid tumor malignanciesR35CA197292 · NCI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2021
$6.2MIN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2MT-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4MGVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9MInducing NK cells to remember and fight cancerR01HL122216 · NHLBI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2018
$1.5MMolecular Programming of Immunological Memory in Human Natural Killer CellsR00HL123638 · NHLBI · UNIVERSITY OF MINNESOTA · PI CICHOCKI, FRANK · 2017 to 2019
$736kMolecular Programming of Immunological Memory in Human Natural Killer CellsK99HL123638 · NHLBI · UNIVERSITY OF MINNESOTA · PI CICHOCKI, FRANK · 2015 to 2016
$190kNCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS R01 CA072669NCI NIH HHS R35 CA197292NHLBI NIH HHS K99 HL123638NHLBI NIH HHS R00 HL123638NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL122216NIAID NIH HHS R01 AI034495
Abstract
Maturation of human natural killer (NK) cells as defined by accumulation of cell-surface expression of CD57 is associated with increased cytotoxic character and TNF and IFNγ production upon target-cell recognition. Notably, multiple studies point to a unique role for CD57
Indexed as
A549 CellsAnimalsAntibody-Dependent Cell CytotoxicityCell Line, TumorEnzyme InhibitorsFemaleGlycogen Synthase Kinase 3HumansImmunotherapy, AdoptiveInterleukin-15K562 CellsKiller Cells, NaturalMiceMice, Inbred NODOvarian NeoplasmsPyridinesChir 99021Enzyme InhibitorsGlycogen Synthase Kinase 3Interleukin-15PyridinesPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03319459ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.